GILD stock news - Gilead Sciences Inc

Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment

businesswire.com Jun 8, 2026 10:35 PM

GILD MRK

Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study

businesswire.com Jun 8, 2026 10:30 PM

GILD MRK

Retool Achieves AWS Consumer Goods Competency

businesswire.com Jun 8, 2026 5:49 PM

AMZN COIN DDOG ADBE NFLX AAPL GOOG CHTR NVDA MSFT INTC AMD TSLA META CRM IBM ORCL CSCO ACN PYPL UPST PLTR SNOW CRWD PANW ZS MDB AFRM SOFI UPWK FIVN DOCU SMCI ASML AMAT KLAC LRCX MU WDC NXPI QCOM MRVL ADSK CDNS SNPS AMGN GILD BMY LLY REGN VRTX BIIB AZN XOM CVX SHEL T VZ TMUS CMCSA DIS GOOGL

As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over Antibodies

accessnewswire.com Jun 8, 2026 2:30 PM

NNVC GILD

Dualitas Therapeutics Appoints Karim Dabbagh as Chief Executive Officer to Advance Novel Bispecific Antibody Pipeline Toward the Clinic

prnewswire.com Jun 8, 2026 1:00 PM

GILD

Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa

businesswire.com Jun 5, 2026 9:00 AM

GILD

Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline

businesswire.com Jun 4, 2026 10:15 PM

GILD LKFT

GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE

globenewswire.com Jun 4, 2026 10:15 PM

GILD

IgE Receptor Antagonists Clinical Trial Pipeline Analysis: 12+ Key Companies Shaping the Future of IgE Receptor Antagonists Therapeutics | DelveInsight

globenewswire.com Jun 4, 2026 7:00 PM

AMRX ARX GSK AZN SNY NVS MRK REGN JNJ PFE BMY LLY VRTX AMGN ABBV GILD BIIB CSL AQST RAPT ALGT

Happening Next Week! C-Level Technology Leadership and the Rise of Iconic Leaders Will Shape the Conversation at HMG Strategy’s 2026 New York CISO Summit. Be a Part of It. Register Now.

globenewswire.com Jun 4, 2026 4:34 PM

MSFT PFE BAC CVS FMS DGX VRTX CMCSA LAB AMZN GOOGL NVDA IBM ORCL AMD INTC META ADBE CRM CSCO ACN TMO UNH JNJ PG XOM CVX KO PEP DIS NFLX TSLA REGN GILD AMGN BMY MRNA BIIB CRSP ROKU DDOG SNOW PANW ZS CRWD SMCI ASML QCOM AMAT MU LRCX KLAC NXPI ON ADI TXN MCHP AVGO MRVL PLTR UPST COIN SOFI PLUG FCEL SPCE GOOG

GILD News

Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment

Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study

Retool Achieves AWS Consumer Goods Competency

As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over Antibodies

Dualitas Therapeutics Appoints Karim Dabbagh as Chief Executive Officer to Advance Novel Bispecific Antibody Pipeline Toward the Clinic

Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa

Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline

GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE

IgE Receptor Antagonists Clinical Trial Pipeline Analysis: 12+ Key Companies Shaping the Future of IgE Receptor Antagonists Therapeutics | DelveInsight

Happening Next Week! C-Level Technology Leadership and the Rise of Iconic Leaders Will Shape the Conversation at HMG Strategy’s 2026 New York CISO Summit. Be a Part of It. Register Now.